NASDAQ:AVRO - Avrobio Stock Price, Forecast & News

Avrobio's stock was trading at $18.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVRO shares have decreased by 8.3% and is now trading at $16.53. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avrobio.

Avrobio is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Avrobio.

Avrobio Inc (NASDAQ:AVRO) released its quarterly earnings results on Monday, March, 16th. The company reported ($0.72) EPS for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.13. View Avrobio's earnings history.

7 analysts have issued 12 month price objectives for Avrobio's shares. Their forecasts range from $24.42 to $43.00. On average, they anticipate Avrobio's stock price to reach $36.24 in the next twelve months. This suggests a possible upside of 119.2% from the stock's current price. View analysts' price targets for Avrobio.

Headlines about AVRO stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avrobio earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAvrobio.

Avrobio saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,551,600 shares, an increase of 6.3% from the February 27th total of 1,460,000 shares. Based on an average daily trading volume, of 241,700 shares, the days-to-cover ratio is presently 6.4 days. Currently, 11.7% of the shares of the stock are sold short. View Avrobio's Current Options Chain.

Some companies that are related to Avrobio include Denali Therapeutics (DNLI), Alector (ALEC), Fate Therapeutics (FATE), Cortexyme (CRTX), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Coherus Biosciences (CHRS), Regenxbio (RGNX), Editas Medicine (EDIT), Twist Bioscience (TWST), Beam Therapeutics (BEAM), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM), I-Mab (BDTX) and Oyster Point Pharma (OYST).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Amarin (AMRN), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Advanced Micro Devices (AMD), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), Zynerba Pharmaceuticals (ZYNE), Biohaven Pharmaceutical (BHVN), Abeona Therapeutics (ABEO) and Aduro BioTech (ADRO).

(AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Avrobio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Tang Capital Management LLC (3.16%), Emerald Advisers LLC (2.07%), State Street Corp (2.03%), Victory Capital Management Inc. (1.41%), Victory Capital Management Inc. (1.32%) and Geode Capital Management LLC (0.93%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View institutional ownership trends for Avrobio.

AVRO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., UBS Group AG, AlpInvest Partners B.V., Victory Capital Management Inc., Nuveen Asset Management LLC, Rafferty Asset Management LLC, Bank of America Corp DE, and Goldman Sachs Group Inc.. Company insiders that have sold Avrobio company stock in the last year include Christopher Paige, and Geoffrey Mackay. View insider buying and selling activity for Avrobio.

AVRO stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Tang Capital Management LLC, FMR LLC, Parkman Healthcare Partners LLC, California Public Employees Retirement System, Spark Investment Management LLC, Nisa Investment Advisors LLC, and UBS Asset Management Americas Inc.. View insider buying and selling activity for Avrobio.

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVRO stock can currently be purchased for approximately $16.53.

Avrobio has a market capitalization of $595.58 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe. View additional information about Avrobio.

The official website for Avrobio is http://www.avrobio.com/.

Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]